ClinicalTrials.gg

Program

denecimig

Also written as “NNC0365-3769 (Mim8)”, “Mim8” and “Denecimig”.

Its studies are mostly in Hemophilia A, led by Novo Nordisk.

Furthest: phase 3, since Sep 13, 20217 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk72 open or runningphase 3since Sep 13, 2021Dec 17, 2019Jun 30, 2028phase 3 · NCT05685238
  • Named in Novo Nordisk’s own pipeline as Denecimig (Mim8) in haemophilia A, phase 4, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2019First study: phase 2 study in Healthy VolunteersFirst studyNCT04204408 · 275 enrolled · United States, Austria, Bulgaria and more
  2. Sep 13, 2021Phase 3 study in Hemophilia ANCT05053139 · 281 enrolled · United States, Austria, Belgium and more
  3. Mar 23, 2022Phase 3 study in Haemophilia A With or Without InhibitorsNCT05306418 · 70 enrolled · United States, Canada, China and more
  4. Jan 4, 2023Phase 3 study in Hemophilia ANCT05685238 · 451 enrolled · United States, Austria, Belgium and more
  5. Jan 4, 2023Phase 1 study in Hemophilia ANCT05681845 · 205 enrolled · Germany
  6. May 12, 2023Phase 3 study in Hemophilia ANCT05878938 · 61 enrolled · United States, Austria, Belgium and more
  7. Sep 15, 2026Phase 3 study in Hemophilia ANCT07830732 · 84 planned · United States, Argentina, Australia and more

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Hemophilia ANCT05685238
  2. Mar 23, 2029Primary completion: phase 3 study in Hemophilia ANCT07830732

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07830732Hemophilia A · United States, Argentina, Australia and more3RecruitingMar 23, 202984
NCT05878938Hemophilia A · United States, Austria, Belgium and more3CompletedJul 18, 202461
NCT05685238Hemophilia A · United States, Austria, Belgium and more3Active, not recruitingJun 30, 2028451
NCT05681845Hemophilia A · Germany1CompletedOct 13, 2023205
NCT05306418Haemophilia A With or Without Inhibitors · United States, Canada, China and more3CompletedNov 13, 202470
NCT05053139Hemophilia A · United States, Austria, Belgium and more3CompletedMar 11, 2024281
NCT04204408Healthy Volunteers · United States, Austria, Bulgaria and more2CompletedOct 6, 2023275

How it is read

Names in the registry

  • “NNC0365-3769 (Mim8)”, 3 entries
  • “Mim8”, 2 entries
  • “Denecimig”, 1 entry
  • “NNC0365-3769 (Mim8) PPX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.